Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesJasper Therapeutics Inc

Jasper Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
14.05 USD -0.71 ( 4.81%)
Last update at 2026-11-12T15:34:00Z
VOLUME
8825
Market Cap
361.75M

Momentum Score

…

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
13.63
Low
14.99
High
52 Week Price Range
4.00
Low
31.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Jasper Therapeutics develops therapies intended to improve outcomes for organ transplant patients and individuals with hematologic disorders, focusing on novel biologic and cell-based approaches. Long-term growth may be driven by successful clinical trial results, regulatory approvals and partnerships addressing substantial unmet needs in transplantation and blood diseases, which could support commercialization and revenue expansion.

Principal risks include clinical and regulatory setbacks, ongoing financing requirements for a clinical-stage company, competition from established therapies and reimbursement uncertainties.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
14.76
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.04
ROE
-112.67%
Net Debt
-84.10M
ROCE
-61.68%
Diluted EPS TTM
-61.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -37.69M -30.64M -31.67M -
Net income -24.17M -23.98M -31.67M -
Selling general administrative 16.57M 11.41M 4.80M -
Gross profit 13.51M 6.20M - -
Reconciled depreciation 0.97M 0.38M 0.00M -
Ebit -51.20M -36.83M -20.68M -4.71M
Ebitda -64.12M -43.11M -9.81M -
Depreciation and amortization -12.93M -6.28M 10.88M -
Non operating income net other - - -5.51M -
Operating income -51.20M -36.83M -20.68M -
Other operating expenses 51.20M 36.83M 20.68M -
Interest expense 13.51M 6.20M 10.99M 0.00M
Income tax expense -13.51M -6.65M -0.04M -
Total revenue 13.51M 6.20M 0.00M -
Total operating expenses 51.20M 36.83M 20.68M -
Total other income expense net 13.51M 6.20M -10.99M -
Net income from continuing ops -51.20M -36.83M -6.48M -
Net income applicable to common shares -37.69M -30.64M -6.48M -4.99M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 95.38M 48.36M 93.65M 23.36M 100.15M
Other current assets 1.80M 2.82M 3.13M 0.15M 0.33M
Total liab 14.68M 12.37M 24.14M 58.49M 3.61M
Total stockholder equity 78.44M 35.99M 69.52M -35.13M 5.00M
Other current liab 7.25M 4.43M 0.79M 2.60M -
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M -
Retained earnings -169.60M -105.14M -67.45M -36.81M 0.00M
Other liab - 2.52M 13.74M 9.01M 4.12M
Other assets 0.00M 1.18M 0.99M 0.64M 0.05M
Cash 86.89M 38.25M 84.70M 19.84M 1.21M
Total current liabilities 12.37M 7.07M 8.02M 4.01M 0.11M
Current deferred revenue - - 2.81M - -
Net debt -84.10M -34.60M -81.82M -18.21M -
Short term debt 0.97M 0.86M 0.51M - -
Short long term debt total 2.79M 3.65M 2.88M 1.62M -
Other stockholder equity 248.04M 92.76M 136.96M 1.68M -
Property plant equipment - 3.57M 4.83M 2.03M -
Total current assets 88.94M 41.73M 87.83M 20.68M 100.15M
Long term investments - - - 100.34M 100.15M
Net tangible assets - 35.99M 69.52M 84.36M 98.08M
Short term investments - - - - 100.15M
Net receivables 0.25M 0.66M 0.70M 0.60M -
Long term debt - - - 13.13M -
Inventory - - 2.41M 0.10M -
Accounts payable 4.15M 1.77M 3.92M 1.42M 0.11M
Accumulated other comprehensive income - - -93.65M - -
Common stock total equity - 0.00M 0.00M 0.00M 0.00M
Retained earnings total equity - -105.14M -67.45M -7.08M 0.00M
Non currrent assets other 1.34M 1.18M 0.99M 0.64M -
Non current assets total 6.44M 6.63M 5.82M 2.67M 100.15M
Capital lease obligations 2.79M 3.65M 2.88M 1.62M -
Long term debt total - - - 13.13M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.58M -2.43M 0.00M -
Change to liabilities 0.41M 3.70M 0.16M 0.54M
Total cashflows from investing activities -0.58M -2.43M 0.20M -2.43M
Net borrowings 0.07M - - 1.50M
Total cash from financing activities 0.06M 100.97M 11.29M 29.13M
Change to operating activities 2.17M -1.92M 0.94M 1.39M
Net income -37.69M -30.64M -31.67M -4.99M
Change in cash -46.38M 64.86M -6.98M 27.16M
Begin period cash flow 85.05M 20.18M 27.16M -
End period cash flow 38.67M 85.05M 20.18M 27.16M
Total cash from operating activities -45.86M -33.68M -18.27M -1.97M
Issuance of capital stock 0.00M 10.75M 11.23M -
Depreciation 0.97M 0.38M 0.38M 0.38M
Other cashflows from investing activities - - 0.20M -
Change to account receivables -0.66M 0.60M 0.60M 0.60M
Sale purchase of stock 0.03M 5.70M - -
Other cashflows from financing activities -0.58M 90.22M 0.20M 89.98M
Change to netincome -8.83M 0.55M 5.89M 1.09M
Capital expenditures 0.58M 2.43M 2.43M 2.43M
Change receivables -0.66M 0.60M - -
Cash flows other operating -0.06M -8.26M -0.21M -
Cash and cash equivalents changes -46.38M 64.86M -0.44M -
Change in working capital -0.65M 1.62M 1.30M -
Stock based compensation 4.09M 1.05M 1.21M -
Other non cash items -12.59M -9.09M 10.90M -
Free cash flow -46.43M -36.11M -18.27M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
JSPR
Jasper Therapeutics Inc		 -0.71
4.81%		 14.05 - - - 5.34 -4.94
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Jasper Therapeutics Inc

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

2200 Bridge Pkwy, Redwood City, CA, United States, 94065

650 549 1400

https://www.jaspertherapeutics.com/

45

Name Title Year Born
Dr. Judith Anne Shizuru M.D., Ph.D. Co-Founder, Chair of Scientific Advisory Board & Director 1957
Mr. Jeetinder Singh Mahal M.B.A. CFO, COO & Corp. Sec. 1973
Dr. Kevin N. Heller M.D. Exec. VP of R&D 1971
Mr. Ronald A. Martell Pres, CEO & Director 1962
Dr. Susan Prohaska Ph.D. Co-Founder and VP of Operations & Program Management NA
Dr. Carol Zoltowski Sr. VP of Regulatory Affairs & Quality 1950
Dr. Wendy Pang M.D., Ph.D. Sr. VP of Research & Translational Medicine NA
Mr. Ronald A. Martell President, CEO & Director 1962
Dr. Judith Anne Shizuru M.D., Ph.D. Co-Founder, Chair of Scientific Advisory Board & Director 1956
Mr. Jeetinder Singh Mahal M.B.A. Chief Operating Officer 1972

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…